HPHwa-Jin Park

Hwa-Jin Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hwa-Jin Park has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Hak-Chul Hyun

    Department of Biomedical Pharmacology, Korea Ginseng and Tobacco Research Institute

    1 shared publication
  • Han-Jae Shin

    Department of Biomedical Pharmacology, Korea Ginseng and Tobacco Research Institute

    1 shared publication
  • Hye-Seon Ham

    Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering, Inje University

    1 shared publication
  • Hyun-Jeong Cho

    Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering, Inje University

    1 shared publication
  • Ki-Hyun Park

    Department of Biomedical Pharmacology, Korea Ginseng and Tobacco Research Institute, Taejon

    1 shared publication
  • Woong-Tak Jun

    Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering, Inje University

    1 shared publication

Latest Publications

  • Open Access

    Possible Role of Ginsenoside Rb1 on Regulation of Rat Liver Triglycerides.

    by Ki-Hyun Park, Han-Jae Shin, Young-Bum Song, Hak-Chul Hyun, Hyun-Jeong Cho, Hye-Seon Ham, Young-Bin Yoo, Young-Chul Ko, Woong-Tak Jun, Hwa-Jin Park

    We have studied the effects of ginsenoside Rb1 (GRb1) on the change in lipid contents in rat liver. When GRb1 was administered intraperitoneally to rats, liver microsomal cytochrome P-450 content and NADPH-cytochrome P-450 reductase activity were lower than those in control rats. The contents of triglyceride (TG) and cholesterol were decreased, but those of total phospholipid, phosphatidylcholine, and phosphatidylethanolamine were increased in the GRb1-treated group compared with controls. These results indicate that GRb1 might be involved in lipid metabolism by regulating the activity of microsomal cytochrome P-450 monooxygenase. Although liver TG levels were reduced by GRb1, the levels of TG and β-lipoprotein in serum from the GRb1-treated group did not change as compared with those in controls. Thus we suggest that the decrease in liver TG levels with GRb1-treatment is not associated with the secretion of TG-rich very low-density lipoprotein. Furthermore, the level of cAMP was also significantly increased in the GRb1-treated group as compared with that in controls. Additionally, the cAMP level was more markedly increased as compared with that in the GRb1-treated group or control group when GRb1 was exogenously added to the reaction system for measuring cAMP production in homogenates from control group liver. Accordingly, these results demonstrate that GRb1 might lower TG levels via cAMP-production in the liver, and GRb1 might be an interesting candidate to for a modulator of cAMP-mediated effects, especially within the liver steatosis system.